For the Treatment of Methicillin-Resistant Staphylococcus Aureus Infections in the Hospital, Trius Therapeutics’ Tedizolid Will Generate Sales of Nearly $150 Million in 2021

For the Treatment of Methicillin-Resistant Infections in the Hospital, Trius Therapeutics’ Tedizolid Will Generate Sales of Nearly $150 Million in 2021

Decision Resources

[email protected]

Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, although the Methicillin-resistant (MRSA) drugmarket is currently dominated by parenteral agents, drug developers have recognized a long-standing need for MRSA agents that are available in interchangeable IV and oral formulations, and several such drugs are poised to launch by 2021. Among these agents is IV and oral tedizolid (Trius Therapeutics), which is likely to earn commercial success owing to its increased MRSA activity, which allows for less frequent dosing, shorter courses of therapy and reduced toxicity compared with Pfizer’s Zyvox. For treatment of MRSA infections in the hospital in key indications (nosocomial pneumonia, bloodstream infections, complicated skin and skin structure/surgical site infections and complicated intra-abdominal infections), Decision Resources expects tedizolid will generate sales of nearly $150 million in 2021 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The Pharmacor advisory service entitled also finds that, through 2021, several other IV and oral agents with MRSA activity are expected to launch including Rib-X’s delafloxacin, Furiex’s JNJ-Q2, Nabriva/Forest’s BC-3781 and Tetraphase’s TP-434. However, the impact of these agents on the overall hospital-treated MRSA market will be small, because of their late entry into a competitive market and only marginal improvements over Zyvox for the treatment of MRSA infections.

The findings also reveal that hospital-treated MRSA infections represent a high-value segment of the overall antibiotics market that will continue to expand with the expected launch of ten new drugs with MRSA activity through 2021. Garnering sales of nearly $775 million in 2011, the hospital-treated MRSA market is poised to grow modestly to greater than $830 million in 2021. The growth in this market will be driven by the uptake of two anti-MRSA agents—ceftaroline (Forest’s Teflaro, AstraZeneca’s Zinforo, Dainippon Sumitomo), which launched in the United States in January 2011, and tedizolid, a second-generation oxazolidinone in Phase III clinical trials for ABSSSI. These two agents stand to capture nearly one-quarter of the 2021 hospital-treated MRSA market.

“The launch of ceftaroline, a first-in-class broad-spectrum anti-MRSA cephalosporin, has expanded the MRSA armamentarium, which previously consisted of primarily narrow-spectrum agents targeted to MRSA,” said Decision Resources Analyst David Holman, Ph.D. “The late-stage MRSA pipeline is diverse and includes both broad- and narrow-spectrum anti-MRSA agents that will give physicians additional options and lines of therapy for the treatment of empiric and confirmed MRSA infections in the hospital.”

Decision Resources () is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at .

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.